| Literature DB >> 33027980 |
Antonio David Mihai1, Cristina Chircov1, Alexandru Mihai Grumezescu1, Alina Maria Holban2.
Abstract
Essential oils (EOs) have attracted considerable interest in the past few years, with increasing evidence of their antibacterial, antiviral, antifungal, and insecticidal effects. However, as they are highly volatile, the administration of EOs to achieve the desired effects is challenging. Therefore, nanotechnology-based strategies for developing nanoscaled carriers for their efficient delivery might offer potential solutions. Owing to their biocompatibility, biodegradability, low toxicity, ability to target a tissue specifically, and primary structures that allow for the attachment of various therapeutics, magnetite nanoparticles (MNPs) are an example of such nanocarriers that could be used for the efficient delivery of EOs for antimicrobial therapies. The aim of this paper is to provide an overview of the use of EOs as antibacterial agents when coupled with magnetite nanoparticles (NPs), emphasizing the synthesis, properties and functionalization of such NPs to enhance their efficiency. In this manner, systems comprising EOs and MNPs could offer potential solutions that could overcome the challenges associated with biofilm formation on prosthetic devices and antibiotic-resistant bacteria by ensuring a controlled and sustained release of the antibacterial agents.Entities:
Keywords: antibacterial nanotherapies; antibiotic-resistant bacteria; essential oils; magnetite nanoparticles; nanoscaled carriers
Mesh:
Substances:
Year: 2020 PMID: 33027980 PMCID: PMC7582471 DOI: 10.3390/ijms21197355
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The advantages and disadvantages of the main EOs extraction techniques [44,45].
| Extraction Method | Advantages | Disadvantages |
|---|---|---|
| Cold Pressing | Lower Temperatures Used During the Process | Low Yield; |
| Solvent Extraction | Lower Temperatures Used During the Process; | Trace Amounts Of Solvent; |
| Enfleurage | Lower Temperatures Used During the Process | Time-Consuming; |
| Steam or Water Distillation | Straightforward Process | High Temperatures Which Can Cause Chemical Changes in the Compounds; |
| Supercritical Fluid Extraction | Low Temperatures Used During The Process; | Lower EOs Quantities |
| Microwave-Assisted Extraction | Reasonable Costs; | Requires Higher Quantities of Organic Solvent; |
| Ultrasound-Assisted Extraction | Minimum Effects on Extractable Compounds; | Expensive |
| Instantaneous Controlled Pressure Drop Process | Enhanced Global Diffusivity; | - |
Figure 1The main bioactive properties of EOs.
Figure 2The main mechanisms involved in the antibacterial activities of EOs. Adapted from “Role of essential oils in food safety: antimicrobial and antioxidant applications” by Bhavaniramya et al., 2019 [25]. ATP = adenosine triphosphate.
Figure 3The main synthesis methods for the preparation of MNPs.
A summary of the main physicochemical properties of magnetite [77].
| Molecular Formula | Color | Density | Melting Temperature | Hardness | Type of Magnetism |
|---|---|---|---|---|---|
| Fe3O4 | black | 5.18 g/cm3 | 1583−1597 °C | 5.5 | Ferrimagnetic |
| Curie Temperature | Saturation Magnetization at 300 K | Standard Gibbs Free Energy of Formation | Crystallographic System | Structure Type | Lattice Parameter |
| 858 K | 92–100 A∙m2/kg | −1012.6 kJ/mol | cubic | inverse spinel | Å = 0.8396 nm |
Where, Å—Lattice constant.
Figure 4The main functionalization strategies for MNPs.
A summary of the MNPs and EOs nanosystems for antimicrobial therapies.
| Microbial Species | Type of Nanosystem | EO Main Constituents | Nanosystem Dimension | MIC Value | Desired Application | Reference |
|---|---|---|---|---|---|---|
|
| Core–Shell MNPs Functionalized with | n.r. | 5 nm | n.r. | Catheter Coating | [ |
| MNPs Functionalized with Patchouli EO | n.r. | 7.5 nm | n.r. | Wound Dressing Coating | [ | |
| MNPs Functionalized with Patchouli, Vanilla, and Ylang Ylang EOs | n.r. | >20 nm | n.r. | Catheter Coating | [ | |
| MNPs Functionalized with | n.r. | 9–10 nm | n.r. | Gastrostomy Tube Coating | [ | |
| MNPs Functionalized with | n.r. | 14–21 nm | 0.62 mg/mL | Antimicrobial Coatings | [ | |
| MNPs Functionalized with Nutmeg EO | Limonene, Terpineol, Carvacrol, and Thymol | 10–15 nm | 250 μg/mL and 125 μg/mL | Antimicrobial Coatings | [ | |
| MNPs Functionalized with Eugenol | - | >10 nm | n.r. | Antimicrobial Coatings | [ | |
| MNPs Functionalized with Eugenol And Limonene | - | 10 nm | n.r. | Wound Dressing Coating | [ | |
|
| MNPs Functionalized with Nutmeg EO | Limonene, Terpineol, Carvacrol, And Thymol | 10–15 nm | 250 μg/mL and 125 μg/mL | Antimicrobial Coatings | [ |
|
| MNPs Functionalized with | n.r. | 9–10 nm | n.r. | Gastrostomy Tube Coating | [ |
| MNPs Functionalized With | n.r. | 14–21 nm | 1.25 mg/mL | Antimicrobial Coatings | [ | |
| MNPs Functionalized with Nutmeg EO | Limonene, Terpineol, Carvacrol, and Thymol | 10–15 nm | 62.5 μg/mL and 31.25 μg/mL | Antimicrobial Coatings | [ | |
|
| MNPs Functionalized with Nutmeg EO | Limonene, Terpineol, Carvacrol, and Thymol | 10–15 nm | 125 μg/mL and 62.5 μg/mL | Antimicrobial Coatings | [ |
| MNPs Functionalized with Eugenol | - | >10 nm | n.r. | Antimicrobial Coatings | [ | |
| MNPs Functionalized with Eugenol And Limonene | - | 10 nm | n.r. | Wound Dressing Coating | [ | |
|
| MNPs Functionalized with Patchouli, Vanilla, And Ylang-Ylang Eos | n.r. | >20 nm | n.r. | Catheter Coating | [ |
|
| Core-Shell MNPs Functionalized with | Limonene, Carvone, and A-Phellandrene | n.r. | n.r. | Antimicrobial Coatings | [ |
| Core-Shell MNPs Functionalized with | n.r. | >20 nm | n.r. | Catheter Coating | [ | |
| MNPs Functionalized with | Carvacrol, γ-Terpinene, p-Cymene, α-Terpinene, and | 10 nm | n.r. | Wound Dressing | [ | |
| MNPs Functionalized with | cis-thujone, eucalyptol, α,β-pinene, and camphene | 13–17 nm | n.r. | Wound Dressing | [ | |
| MNPs Functionalized with | Eucalyptol, Camphor, Caryophyllene, | >20 nm | n.r. | Catheter Coating | [ | |
| MNPs Functionalized with | n.r. | 9–10 nm | n.r. | Gastrostomy Tube Coating | [ | |
| MNPs Functionalized With | n.r. | 14–21 nm | 0.62 mg/mL | Antimicrobial Coatings | [ | |
|
| Core-Shell MNPs Functionalized with | limonene, carvone, and α-phellandrene | n.r. | n.r. | Antimicrobial Coatings | [ |
| MNPs Functionalized with | eucalyptol, camphor, caryophyllene, | >20 nm | n.r. | Catheter Coating | [ | |
|
| Core-Shell MNPs Functionalized with | limonene, carvone, and α-phellandrene | n.r. | n.r. | Antimicrobial Coatings | [ |
|
| Core-Shell MNPs Functionalized with | limonene, carvone, and α-phellandrene | n.r. | n.r. | Antimicrobial Coatings | [ |
| Core-Shell MNPs Functionalized with | n.r. | >20 nm | n.r. | Catheter Coating | [ | |
|
| Core-Shell MNPs Functionalized with | limonene, carvone, and α-phellandrene | n.r. | n.r. | Antimicrobial Coatings | [ |
| Core-Shell MNPs Functionalized with | n.r. | >20 nm | n.r. | Catheter Coating | [ | |
|
| MNPs Functionalized with | n.r. | 9–10 nm | n.r. | Gastrostomy Tube Coating | [ |
Where, n.r.—not related; “-” not applicable.